Mentions
Extended reach
Total likes
Video views
AI synopsis
The collection centers on a meta-discussion of the SELECT trial (Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes). Most posts highlight the 20% reduction in major cardiovascular events in non-diabetic overweight/obese individuals with preexisting cardiovascular disease, underscore the trial’s size and duration, and discuss broader implications for obesity treatment, access, and health policy. Tone ranges from enthusiastic endorsement of cardiovascular benefits to cautious notes about conflicts of interest, cost, and applicability to different BMI ranges or normal-weight patients. Word choices such as “significant reduction,” “heart protection,” and “world-changing” convey optimism, while caveats about adverse events and study design reflect critical engagement.
Overall tone is supportive of the study's findings, with some skepticism about conflicts of interest and applicability, leading to moderate agreement.
Very high interest across posts, many referencing data, trials, and implications for practice.
Engaged discussions with references, questions, and critiques, though some posts are merely sharing links or praising the trial.
Notable potential impact discussed (policy, access, cost, reclassification), but some skepticism about generalizability and real-world uptake.
「柳叶刀：“减肥神药”司美格鲁肽或是减重最佳药物，还可治疗心衰」 司美格鲁肽（Semaglutide），是胰高血糖素样肽1（GLP-1）受体激动剂，能够模拟其作用，抑制食欲，减少饮食摄入，已经被批准用于治疗2型糖尿病与有效减重。 https://t.co/FNjdnmUAij
Pues ahora sí #arGLP1 #Semaglutida #SELECT ❤️
Only 12 of the 15 Study Authors have direct affiliation with the drugs manufacturer Novo Nordisk. However don’t worry they have all declared that despite their conflicts of interest they in fact have none to declare. ??♂️ So ask your doctor if Novo Nordisk’s GLP-1 receptor
@mikex163 @StatisticUrban Guess you didn't read the paper, "Semaglutide and Cardiovascular Outcomes **in Obesity** without Diabetes." The semaglutide group lost 10% of their body weight, on average. https://t.co/RowvS3ufXn
Steven Kahn •Position: Advisory roles in several pharmaceutical companies •Interests: •Advisory board member for AltPep, Anji Pharmaceuticals, Boehringer Ingelheim, Eli Lilly, Intarcia, Merck, Novo Nordisk •Manuscript Title: “Semaglutide and Cardiovascular Outcomes in
Here is the trial: https://t.co/OCg6OzBDVP
Explores weight loss from semaglutide in obesity over 68 weeks and how most of the gains fade during a 1-year withdrawal, with diminishing cardiometabolic benefits. Highlights the need for ongoing care to sustain health…
Semaglutide reduces cardiovascular risks in obese individuals without diabetes, lowering instances of heart attacks, strokes, and death from heart causes. The study involved over 17,600 participants and demonstrated the…
Semaglutide, a drug known to reduce heart problems in diabetic patients, was tested to see if it can also lower cardiovascular risks in overweight or obese people without diabetes who already have heart disease.
This video reviews the 2024 nephrology and hypertension study highlights, focusing on semaglutide's benefits. The study shows semaglutide significantly reduces major cardiovascular events in overweight or obese…
This video provides a clear, study-based explanation of whether Ozempic, Wegovy, and Mounjaro weight loss pens cause rebound effects, why they happen, and how to avoid regaining lost weight. Designed for safe…
This week, Dr. John Mandrola discusses the PREVENT score, GLP1 mechanism in cardiovascular disease, statin benefits, and issues with hospitalization endpoints in heart failure trials. Key insights include comparing…
This week in cardiology discusses the VENTOUX study on endurance athletes and arrhythmias, the ongoing debate between rate and rhythm control in atrial fibrillation, and the role of GLP1 drugs. The importance of…
This podcast covers vulnerable plaque, industry payments to trainees, and the trial design of tirzepatide versus dulaglutide. Insights on major adverse cardiovascular events in type 2 diabetes patients are discussed…
This week, John Mandrola MD discusses screening for valvular heart disease, the efficacy of multivitamins, and the role of CPAP in preventing cardiovascular events in sleep apnea patients. The insights highlight recent…
The video discusses the latest findings in cardiology, including an Impella update, the TAVI vs SAVR trial, and studies on angina and PCI. Focused on percutaneous coronary intervention, it examines its impact on…
Explains how semaglutide alters appetite and weight loss, why it lasts a week in blood, common side effects, and what happens after stopping treatment.
This video explores the role of GLP-1 receptor agonists in addressing obesity and other health issues. It reviews recent innovations, their effectiveness in treating obesity, heart disease, and neurodegenerative…
This video discusses a study showing semaglutide lowers cardiovascular risks in overweight or obese individuals without diabetes, with fewer heart-related events observed in over 17,600 participants, highlighting its…
Semaglutide reduces major cardiovascular events in overweight or obese patients without diabetes, showing promise for enhancing heart health in high-risk populations.
Join our scientific team as we discuss the three most impactful clinical papers of November 2023. This month’s highlights include a study on dapagliflozin in myocardial infarction without diabetes, showcasing its…
This week’s podcast reviews significant trials including NOAH-AFNET 6 and ARTESiA that highlight the role of direct oral anticoagulants (DOACs) in preventing ischemic stroke among patients with device-detected atrial…
GLP1 medications, identified in the 1980s and FDA-approved since 2005, play a crucial role in blood sugar control by increasing insulin production. Clinical trials show significant weight loss averaging 15%, with…
Summarizes recent findings on GLP-1 drugs like Ozempic/Wegovy/Mounjaro, their real benefits, risks, and the need for careful medical guidance.
Semaglutide: about 65 in 1,000 had a heart attack, stroke or died from heart disease, versus 80 on placebo over ~3 years. Adults had heart or blood vessel disease and excess weight, no diabetes. More stopped for side effects. SELECT (2023): https://t.co/VPzOK8x5f2 https://t.co/TzUpYAvOIt
@RomeoNovem66215 @mxyplyk @newstart_2024 @fluffyguy @ClubShayShay Well your best friend is a retard. Ozempic “dissolves” hearts and diaphragms is the dumbest thing I've heard. Semaglutide has actually reduced cardiovascular events in several large clinical trials. Feel free to post your study or kindly stfu. https://t.co/sQS4Ol7cx5
Si está buscando un método para bajar de peso y en redes le dicen que lo puede conseguir solo con alimentación y/o otras personas solo con medicamentos, tal vez le están contando la mitad de la historia. Lea este artículo para entender mejor. https://t.co/A7A8QICpLQ
https://t.co/33sU2XujtL
https://t.co/VlmxMfjHCn
Fuente: Lincoff et al., New England Journal of Medicine 2023. https://t.co/U50FF4zoxt Foto: Chemist4U, CC BY-SA 2.0
Sources: https://t.co/236LpF58no https://t.co/XkAEwXzXEH
Sources: https://t.co/XkAEwXzXEH https://t.co/CM7cHaqFTz
17,604 people with heart disease and a BMI over 27 (overweight), no diabetes, took semaglutide or a placebo for 3 years. Heart attack, stroke or cardiovascular death: 6.5% against 8.0%. Side effects stopped the drug in 17%, against 8% on placebo. https://t.co/mZrOQSHocH
SELECT: 6.5% vs 8.0% had a cardiovascular event. Participants already had cardiovascular disease; this is not proof of universal lifespan extension. New England Journal of Medicine (2023) pubmed.ncbi.nlm.nih.gov/37952131/ AI-assisted. Educational, not medical advice.
12/ Selected references — Thread 3: Obesity: Prevention AND Treatment Not comprehensive, but these are several of the principal sources underlying the thread: • WHO. Obesity and overweight. Updated 2025. Overview of obesity as a chronic, relapsing, multifactorial disease and
The numbers, straight: Appetite: about 24% less food a day. STEP 1, no diabetes: weight down 14.9% at 68 weeks, vs 2.4% on placebo. SELECT, heart disease, no diabetes: major heart events down 20%. Source: https://t.co/gx7FLpageh Source: https://t.co/vNYWS0kjXE
@XainzaP The CV data made this concrete: SELECT (17,604 adults, overweight/obesity + CVD, no diabetes) cut major cardiovascular events 20% with semaglutide — treating obesity itself moved hard outcomes, and trial design followed. https://t.co/rZHgqy81I9
The papers, so you do not have to take our word for it: Diabetes Obes Metab 2017: 10.1111/dom.12932 N Engl J Med 2021: 10.1056/NEJMoa2032183 N Engl J Med 2016: 10.1056/NEJMoa1607141 N Engl J Med 2023: 10.1056/NEJMoa2307563
Can we talk about the heart data for a second? In SELECT, semaglutide reduced major cardiovascular events in adults with heart disease and overweight/obesity, without diabetes. That's a hell of a finding. https://t.co/yGfN9N8OTq https://t.co/dcirl8o3yR
@Josh_fitcheck13 Context: SELECT showed semaglutide cut MACE by 20% in people without diabetes, so the bar is set. Tirzepatide's dedicated CV-outcomes trial is still pending — different evidence stages, not a fair race yet. https://t.co/rZHgqy81I9
Aquí te dejo los links: Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221-2232. doi:10.1056/NEJMoa2307563. https://t.co/FFML8Z3PaX Wong CK, Drucker DJ. Antiinflammatory actions
心血管疾患の既往がある場合、糖尿病がなくても肥満による脳卒中の予防に GLP-1 受容体作動薬を考慮してもよい。 （脳卒中ガイドライン 推奨度 C エビデンスレベル低）。 Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes PMID 37952131 https://t.co/MEbqzD3JDq https://t.co/xQegdvjCky
Sources: SELECT cardiovascular outcomes: https://t.co/7QefVDbZBQ FLOW kidney outcomes: https://t.co/QFsH5N2hnJ Rotator cuff repair cohort: https://t.co/K7kQQPs15d
@SamaHoole One question settles the whole exchange: name the randomized trial, any endpoint, any duration, any size, of the protocol the coaching sells. While that search runs, the other side of the ledger is here. SELECT https://t.co/X3etcX85rf, SEMALCO https://t.co/crBH3XuEYR, and the
@Lee_tilson123 @ZlyukaKoshka @ElizabethRBess @daveryder @krassenstein + link for studies for some light reading https://t.co/h9nvZ7t5pm https://t.co/c0VIjw2DlI
@Msk20Kushe Yes, we’ve seen the reduction in SELECT (Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes), and we’re currently waiting on SURMOUNT-MMO, a similar tirzepatide trial looking at cardiovascular outcomes (among others) in patients with obesity and without T2D. https://t.co/5oxAlVbVLI
Special update: progress extending healthy years after 65 is real (GLP-1, SGLT2, BP, strength). Max human lifespan extension? Still unproven. #HealthOptimization #Longevity #PreventiveHealth https://t.co/3jSzBms3VW
https://t.co/14MVVqosn7
Science News: Could your wellness routine secretly protect your heart and extend your life? Recent clinical findings show that GLP-1 agonists offer significant protection for your cardiovascular system, reducing major risks by 20%. This benefit works independently of weight https://t.co/DoGS1fADzc
Science News: Könnte eine einfache Spritze dein Herz schützen und das Altern verlangsamen? Eine große klinische Studie mit über 17.000 Teilnehmern belegt, dass GLP-1-Präparate das Risiko für schwere Herzereignisse wie Herzinfarkte um 20 % senken können. Erstaunlicherweise bietet https://t.co/c3hHz2xSQL
https://t.co/i72EVYE71g
The trial: Lincoff et al., SELECT. N Engl J Med 2023. https://t.co/mEWIGlSh1G
? References & Further Reading The thread above is a thought experiment about the potential public-health implications of broadly accessible GLP-1 therapies. The underlying evidence comes from a rapidly expanding body of clinical research: • Wilding JPH et al. (2021).
https://t.co/n4eMmgOG7S
6/ GLP-1RA and dual GIP/GLP-1 agonists ⬇️ HF risk in high-rosk CKD ?SELECT (obesity + CVD, eGFR 80): semaglutide ⬇️ HF events regardless of eGFR https://t.co/ui3wAiXwqi ?FLOW (T2D+CKD, eGFR 45), semaglutide ⬇️ reduced 1st HF events by 27% with modest weight loss
https://t.co/mqqLXEeay6
https://t.co/ESlTEDIvHJ
https://t.co/2DHZCHwxKL
SELECT changed the semaglutide conversation from weight loss to cardiovascular risk. 17,604 adults. Overweight or obesity. No diabetes. Lower major cardiovascular events with semaglutide 2.4 mg. PubMed: https://t.co/gJ5VNp7AuC Is heart protection now the real GLP-1 headline?
https://t.co/KVYSXK5N3H
SELECT is the trial that changed Wegovy from a weight loss story into a cardiovascular-risk story. Semaglutide cut major adverse cardiovascular events by 20% in people with obesity or overweight and established CVD, without diabetes. PubMed: https://t.co/gJ5VNp7AuC What
Semaglutide reduces major cardiovascular events in people with obesity without diabetes (SELECT trial) www.nejm.org/doi/full/10....
8D/ Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. PMID: 37952131 | DOI: 10.1056/NEJMoa2307563
Is semaglutide now a heart medicine? What the 17,000‑person SELECT trial really showed. In high‑risk people with heart disease and extra weight but no diabetes, this “skinny jab” also clearly lowered heart attacks and strokes over several years. Weekly semaglutide 2.4 mg cut https://t.co/7zBRkAWOgb
Yikes. The evidence he cited to warn you off a drug with 17,604 patients enrolled ten... Follow along if you please. @SteveBennettMhP runs Clubwell, an app positioned around "real food" empowerment as the alternative to pharmaceutical obesity treatment. His Clubwell members https://t.co/kD5dpqq6p9
Yikes. The evidence he cited to warn you off a drug with 17,604 patients enrolled ten... Following along if you please. @SteveBennettMhP runs Clubwell, an app positioned around "real food" empowerment as the alternative to pharmaceutical obesity treatment. His Clubwell https://t.co/kD5dpqq6p9
The least interesting metric in his post is the one attached to a 20% reduction in heart attacks and strokes across 17,604 patients. His five "more interesting" ones are predictors. Weight is a lever. Precious. @dr_sumit_sharma runs a direct-to-consumer "precision metabolic https://t.co/sz62mhnZuX
@cwhogg @maxmarchione Here’s a couple just off the list I keep for clients: - Wilding JPH, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. - Lincoff AM, et al. (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. -Perkovic V, et al. (2024).
https://t.co/0pEHQpjpm2
【SELECT試験】 Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes 肥満・過体重かつASCVDを有する非糖尿病患者において、セマグルチド2.4 mgはMACEを20%低下させました。 心不全合併例でも、効果は一貫していました。 #研究キャリアサポート橘
96. Semaglutide 2.4 mg once weekly reduced major adverse cardiovascular events (MACE) compared with placebo in adults with overweight or obesity and established cardiovascular disease without diabetes, demonstrating cardiovascular benefit of GLP-1 receptor agonism beyond glycemic
All the trials and studies i have talked about 1. Wadden TA, Bailey TS, Billings LK, Davies M, Frias JP, Koroleva A, et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: The STEP
In Obesity Best-in-class Diabetes Prevention In patients without diabetes but with obesity, one of the important metabolic endpoints is how many patients end up with diabetes at the end of the trial compared to the placebo group. In a 2025 analysis, out of 1032 patients with https://t.co/Ml4RUQ1OCo
@KrutikaKuppalli @krutikakuppalli Dr. Kuppalli, With respect for your expertise in infectious diseases, I must challenge your dismissal of the FDA memo as "baseless misinformation." As a retired Canadian Marine SAR specialist who's spent years dissecting the data on these synthetic mRNA and
3/4 The original results (a significant reduction in major adverse cardiovascular events) were reported (https://t.co/rzKNwKW6WN) in 2023 when the trial was complete and ultimately led to an FDA approval (https://t.co/C70Sbtua06) for a new indication.
RT @BoussageonR: @tolquen @Fraslin Tout d'abord, l'angioplastie n'était peut être pas indiquée Ensuite, oui, il y a un essai chez des patie…
@tolquen @Fraslin Tout d'abord, l'angioplastie n'était peut être pas indiquée Ensuite, oui, il y a un essai chez des patients non diabétique en prévention secondaire : https://t.co/dLrN6kQzLF
【論文紹介】SELECT試験：セマグルチドが肥満患者の心血管アウトカムを有意に改善。主要CVイベントリスクを20%低減、糖尿病の有無にかかわらず効果を示した。肥満治療薬の枠を超えた臨床的意義。#薬剤師 #肥満症 #論文紹介 参考: NEJM https://t.co/zr4QeR6E5G
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes | New England Journal of Medicine https://t.co/z2i9Z93Iro
Sources: https://t.co/uJ4iDyvR8k https://t.co/CULvYKvaaI, https://t.co/AaezGTp87r, https://t.co/YGftJ0SREC https://t.co/1LYWFpneIT
@bIiccy @RespectElves If that's your worry, then don't worry. GLP-1RAs directly help with heart stuff. Check out the SELECT trial, for example: https://t.co/YGftJ0SREC https://t.co/tLZYSD0ngI
@AnilMakam I've said that before as well, but it can't be taken as a hard-and-fast rule. With GLP-1RAs, several RCTs have shown immediate divergence for different outcomes. For example, here's the composite cardiovascular endpoint in the SELECT RCT: https://t.co/YGftJ0Tpua https://t.co/CaHM8aS2qD
And yes—GLP-1s reduce more than just weight. The SELECT trial showed:
www.nejm.org/doi/full/10....
RT @BevTchangMD: If you’re in Delhi, Chennai, or Mumbai in the next 4 days, say
RT @BevTchangMD: If you’re in Delhi, Chennai, or Mumbai in the next 4 days, say
RT @BevTchangMD: If you’re in Delhi, Chennai, or Mumbai in the next 4 days, say
If you’re in Delhi, Chennai, or Mumbai in the next 4 days, say
If you’re in Delhi, Chennai, or Mumbai in the next 4 days, send me a
https://t.co/l3M2OPZVNf
RT @MediCasos: @Samuelc3c4adnd1 @AcidoRinon @BioTrustNut De nada: https://t.co/Gni4ooDWMF
RT @MediCasos: @Samuelc3c4adnd1 @AcidoRinon @BioTrustNut De nada: https://t.co/Gni4ooDWMF
RT @cremieuxrecueil: Essentially the whole chronic disease crisis can be substantially remedied, and knock-on benefits can be obtained, fro…
@Heidi8361149582 @MdBreathe No. If anything, it prevents heart attacks and is a good thing. https://t.co/jdlVcm2Q9W
RT @cremieuxrecueil: Essentially the whole chronic disease crisis can be substantially remedied, and knock-on benefits can be obtained, fro…
RT @cremieuxrecueil: Essentially the whole chronic disease crisis can be substantially remedied, and knock-on benefits can be obtained, fro…
RT @cremieuxrecueil: Essentially the whole chronic disease crisis can be substantially remedied, and knock-on benefits can be obtained, fro…
Essentially the whole chronic disease crisis can be substantially remedied, and knock-on benefits can be obtained, from getting GLP-1RA prices down and access up. Sources: https://t.co/GTGczLASsF https://t.co/YGftJ0Tpua https://t.co/l9Ibpnglxl
RT @MediCasos: @Samuelc3c4adnd1 @AcidoRinon @BioTrustNut De nada: https://t.co/Gni4ooDWMF
@Samuelc3c4adnd1 @AcidoRinon @BioTrustNut De nada: https://t.co/Gni4ooDWMF
RT @a_fisiolog57853: ENTREVISTA A DANIEL J. DRUCKER ¡¡¡A leer, zagales!!! https://t.co/zev22XLKQ4 El ensayo SELECT: https://t.co/1AFq4iO…
ENTREVISTA A DANIEL J. DRUCKER ¡¡¡A leer, zagales!!! https://t.co/zev22XLKQ4 El ensayo SELECT: https://t.co/1AFq4iOfcq https://t.co/YsfpMQf0EH
@SCDawgin @PaulSkallas First of all, this counts as being tested in humans. Secondly, this drug, and more broadly this class of drugs, has been used in obese people for more than a few years. Third, allow me to introduce you to the SELECT trial which is one example https://t.co/Ijh4UoTCrA
RT @Fmhub_org:
RT @Fmhub_org: Thank you, Dr. Manar Al Ghamdi ,for your insightful and evidence-based presentation on “Semaglutide and cardiovascular outco…
Thank you, Dr. Manar Al Ghamdi ,for your insightful and evidence-based presentation on “Semaglutide and cardiovascular outcomes in obesity without diabetes”. Your clear articulation of the clinical implications and emerging data provided us with a valuable perspective on a https://t.co/1oSBFuemjs
Thank you, Dr. Manar Al Ghamdi ,for your insightful and evidence-based presentation on “Semaglutide and cardiovascular outcomes in obesity without diabetes”. Your clear articulation of the clinical implications and emerging data provided us with a valuable perspective on a https://t.co/85gX3InfRK
Bibliography 1. U.S. Food and Drug Administration. (2005, April 28). FDA approval letter: Byetta (exenatide) injection. https://t.co/DA8hsMAs3T 2. Gottlieb, S., & Johnson, B. (2022). Exenatide. In StatPearls (updated 2024). StatPearls Publishing. 3. Kristensen, S. L., Lee, M.
@yoursimmo Meaningless, semeglutide (Ozempic) improve cardiovascular outcomes in ever RCT I’ve found, here’s one of 17000+ patients https://t.co/eG9hJ7BqKJ
Viste esto @Krusty_M_D ?? https://t.co/tJuVUA86yB
@DustinSears9 @DrNadolsky I think that medicines that prevent heart attacks are good. But to be fair I am a cardiologist, so I may be biased in this opinion. https://t.co/jx9bPVqBgX
Pros and Cons per medcical AI of Ozempic (semaglutide): Pros: 1. Glycemic Control: Semaglutide significantly reduces HbA1c levels, making it effective for managing type 2 diabetes.[1] 2. Weight Loss: It induces substantial weight loss in patients with type 2 diabetes and those
@ourvcore https://t.co/Fz6oJWwpEy importante revisar suas considerações sobre ser para diabetes. Como disse: droga comprovadamente eficaz, segura, estudos com benefícios robustos. NEJM, 2023
@perfaitement @HALLONSA @AsfyXi @Schmidtjnb Det är visat specifikt för fetma och är det första medlet som minskar ’all cause mortality’ hos överviktiga utan diabetes (och även stroke och ickedödliga hjärtinfarkter) Finns flera studier nu men här är en av de första. https://t.co/HPKMmKH1SA
@TheMFingCOO @bava23 @LighthouseDPC @SaroshDin @drmoneymatters Problem Alan is obesity is more than just weight. Increase cardiovascular disease for example. Now we have data that says these drugs REDUCE heart attacks/strokes. So it’s more than losing 10-15%. What is the cost of a MI/stroke to a heath system? https://t.co/p6sXkDCXAK
@danielsoranz a pesquisa é esta: https://t.co/kbDw3nbCQb
I read the thread, the comparison to Fen Fen and "shortcuts" is not the right message, look at this trial in people with obesity WITHOUT diabetes www.nejm.org/doi/full/10....
@GeneInvesting @WexCapital @DmitryKovalchuk @Anonym64382296 @A_May_MD so you think people with BMI in their 30s who have probably struggled with weight for most of their adult lives shouldn't take GLPs I don't know what to say man. CVOT clearly disagrees with you there: https://t.co/TUWZl1Cxjx
@SkimmeLAN @newstart_2024 https://t.co/Kb7vPR48M7
Diet and exercise work well with prevention but suck at treatment. Cf control group in the select study. https://t.co/Kb7vPR48M7 https://t.co/1YDOWxubw5
@newstart_2024 Control group which included diet and exercise really stunk in the treatment of obesity. https://t.co/Kb7vPR48M7
RT @EAPCPresident: 3 days to go before the EAPC Journal Club : read the publication "Semaglutide and Cardiovascular Outcomes in Obesity wit…
RT @EAPCPresident: 3 days to go before the EAPC Journal Club : read the publication "Semaglutide and Cardiovascular Outcomes in Obesity wit…
RT @EAPCPresident: 3 days to go before the EAPC Journal Club : read the publication "Semaglutide and Cardiovascular Outcomes in Obesity wit…
RT @EAPCPresident: 3 days to go before the EAPC Journal Club : read the publication "Semaglutide and Cardiovascular Outcomes in Obesity wit…
RT @EAPCPresident: 3 days to go before the EAPC Journal Club : read the publication "Semaglutide and Cardiovascular Outcomes in Obesity wit…
RT @EAPCPresident: 3 days to go before the EAPC Journal Club : read the publication "Semaglutide and Cardiovascular Outcomes in Obesity wit…
RT @EAPCPresident: 3 days to go before the EAPC Journal Club : read the publication "Semaglutide and Cardiovascular Outcomes in Obesity wit…
3 days to go before the EAPC Journal Club : read the publication "Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes" A. Michael Lincoff et al., N Engl J Med 2023;389:2221-2232, DOI: 10.1056/NEJMoa2307563 https://t.co/7WxadI9GlX https://t.co/GXsSnyZ6BI
RT @gbiondizoccai: Dont' miss the next EAPC Young Community Journal Club discussing the article by Lincoff et al entitled Semaglutide and C…
Dont' miss the next EAPC Young Community Journal Club discussing the article by Lincoff et al entitled Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes, scheduled for next week, January 30, from 17:00 to 18:00 CET myesc.escardio.org/esc_applicat...
Dont' miss the next EAPC Young Community Journal Club discussing the article by Lincoff et al entitled Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes, scheduled for next week, January 30, from 17:00 to 18:00 CET https://t.co/gWgQOuONke https://t.co/5SM840ABXS
Fil 1) Les résultats de l'étude SELECT : www.nejm.org/doi/full/10....
Join our webinar NOW on YouTube. Part 2 of our top-rated studies in the field of nephrology and hypertensiology 2024. Our final countdown! youtu.be/rQFKyMoneQ8?... Our guests: Timotheus Speer Matthias Girndt Mariam Abu Tair
Join our webinar NOW on YouTube. Part 2 of our top-rated studies in the field of nephrology and hypertensiology 2024. Our final countdown! https://t.co/ZWKe437WjN Our guests: Timotheus Speer Matthias Girndt Mariam Abu-Tair https://t.co/rJ653BjTtk
Our final countdown 2024 @MarkusAtHome @MarcusSaemann @AntMarlies @AKronbichler Best of Nephrology Hypertension II https://t.co/HafpmaSebV via @YouTube
@Pesamenteir0o @davebluntsmusic Looks like it helps with cardiovascular health https://t.co/PP66sn2BKe It also may have benefits for people with Alzhiemer's https://t.co/Wv65jluF9C So aside from basic side effects or a major reaction, looks like it's a pretty stable drug.
Here comes @NephJC Top 10 2024. We will follow with our ???? Top 7 on Friday! https://t.co/b6ixY6vWh3 @MarcusSaemann @AKronbichler @AntMarlies https://t.co/WjmXNMbg8H
@ArtCandee I’m vaxed so I’m not a crazy anti- vax person. Had my pneumonia & flu shots 2 weeks ago. Please don’t tell me u think the CV trials were comparable to the SELECT trial. https://t.co/2MZJfutKXu
@Aaron18_Music @SxarletRed the societal pressure of *checks notes* living longer: https://t.co/vAK3MVbm6l
@JayDSarkar @ThiccStauskas There are also more recent studies showing significant cardiovascular benefit, specifically: https://t.co/vAK3MVbm6l
RT @Obesidades_mx: @ConscienHealth Fuentes: -Conscien Health. 2024. Disponible en: https://t.co/sdhwetXopB -Lincoff AM, et al. Semaglutide…
@ConscienHealth Fuentes: -Conscien Health. 2024. Disponible en: https://t.co/sdhwetXopB -Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023.
RT @ethanjweiss: It’s amazing to see the SELECT trial results. Blown away that there is a significant risk reduction in a group of patient…
RT @kevinnbass: Reference https://t.co/eBol4ZNJtL
Reference https://t.co/eBol4ZNJtL
6. If by benefits of the drug you mean weight, glycemic, cardiac, renal, vascular, and OA (among other forthcoming indications), the impacts are persistent: https://t.co/mPQur3Hjzy https://t.co/p4k8UTTuMQ https://t.co/XNvGAzKWur https://t.co/dvV9IH2EHE https://t.co/BHSslgz3Xr
@ALemonDropShot @FrancisPSantora @LaGrecca333 https://t.co/TAUVWcWSGi
@SRHNarborough @cremieuxrecueil @woke8yearold Yes. https://t.co/8g96A18A5Y https://t.co/bQ4M9Veb6g https://t.co/xeyTEsCesQ https://t.co/BWCzqfwqWX https://t.co/RCMlT48Uoz
@MichaelMindrum @MithridatesMD @calleymeans Forgive me, but it looks like the trial was semaglutide vs placebo in non-diabetics and not ozempic vs. diet and lifestyle change in diabetics. And only followed for 39 months? https://t.co/hwMVK5fo5I
@Maesun196924 @MichaelMindrum @calleymeans Here’s the phase 3 that was done to date, others are due in the coming years as well https://t.co/AXsCK67TY5
Semaglutide and cardiovascular outcomes in obesity without Diabetes (Select trial) è lo studio che ci parla degli effetti cv che Semaglutide ha sui soggetti obesi anche SENZA diabete. #itacarep #itacarepyoungcommunity https://t.co/gUA2Kgudvq
RT @descibro: This paper published in the New England Journal of Medicine, showed GLP-1 drug reduced risk of death by 20% https://t.co/Ko…
https://t.co/wBsWgazWiH
This paper published in the New England Journal of Medicine, showed GLP-1 drug reduced risk of death by 20% https://t.co/KoESsl7qZb $GLP1 https://t.co/pQfqFQXriF
@UrgentKarr @jackmurphylive @FitFounder How about you read the cardiovascular outcomes studies in actual humans (non-diabetics and diabetics)? https://t.co/2QfrIf22at https://t.co/34DfC0vd8h
@FitFounder Link to actual human studies: In diabetics: https://t.co/34DfC0vd8h In non-diabetics: https://t.co/2QfrIf22at
@FitFounder And actual large cohort studies on thousands of humans show a clear benefit on CVD: https://t.co/e5KkR5bixk
@KetoCarnivore A rodent study is terrible news? Really? You know that semaglutide improves cardiovascular outcomes in humans, right? https://t.co/xHxf8CupxZ
@gameofchance3 @helen_mrow @Babygravy9 Except those on Ozempic see improvements in heart health vs those on placebo? https://t.co/W9SxNzEXuQ this is one of the largest trials I’ve been able to find and it clearly shows benefits with treatment vs without
Interesting read. Repurposing GLP-1 agonists for Alcohol Use Disorder? Summarizing a large cohort Swedish study & REWHARD consortium. 1.? GLP-1 Agonists & Alcohol Use Disorder (AUD): Glucagon-like peptide-1 receptor agonists (GLP-1), such as semaglutide and liraglutide,
@lukedavid @henri_mourant @AnalyticsGenius https://t.co/tBw3bzMyEC Nice Job!
- https://t.co/Gni4ooEuCd
@thestoptv With preexisting cardiovascular disease and overweight or obesity but without diabetes, weekly subcutaneous semaglutide was superior to placebo in reducing the incidence of death from cardiovascular causes, nonfatal myocardial infarction/stroke. https://t.co/i2voBaYzgn
With preexisting cardiovascular disease and overweight or obesity but without diabetes, weekly subcutaneous semaglutide was superior to placebo in reducing the incidence of death from cardiovascular causes, nonfatal myocardial infarction/stroke https://t.co/i2voBaY1qP https://t.co/Nc7YHmYB8p
@thestoptv In patients with preexisting cardiovascular disease and overweight or obesity but without diabetes, weekly subcutaneous semaglutide at a dose of 2.4 mg was superior to placebo in reducing the incidence of death from cardiovascular causes… https://t.co/i2voBaY1qP
@partsmath @newstart_2024 Claim: The muscle loss from semaglutide causes an age-related acceleration that will result in increased mortality. Complete speculation in every part. And given that semaglutide reduces *ALL-CAUSE MORTALITY*, it's not every plausible speculation. https://t.co/xHxf8CupxZ
@mgourmelon L'efficacité (perte de poids, baisse de mortalité spécifique, baisse des évènements CV) est prouvée par un essai de qualité. https://t.co/Ee3tFlv00Q on attend la mortalité totale (qui baisse avec le Zepbound)
RT @EdCara4: @HomoDorkimus @partiallypro @CNLiberalism This is not true. There have been several large-scale clinical trials of Wegovy (the…
@HomoDorkimus @partiallypro @CNLiberalism This is not true. There have been several large-scale clinical trials of Wegovy (the actual version of semaglutide approved for weight loss) finding a clear benefit on reduced heart, kidney disease, at least in ppl at higher risk. https://t.co/ATi7NqGOqF
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes | New England Journal of Medicine https://t.co/FhF7MxKak3
RT @JoshWalkos: Here is the trial: https://t.co/OCg6OzBDVP
RT @JoshWalkos: Here is the trial: https://t.co/OCg6OzBDVP
RT @JoshWalkos: Here is the trial: https://t.co/OCg6OzBDVP
RT @JoshWalkos: Here is the trial: https://t.co/OCg6OzBDVP
RT @JoshWalkos: Here is the trial: https://t.co/OCg6OzBDVP
RT @JoshWalkos: Here is the trial: https://t.co/OCg6OzBDVP
RT @JoshWalkos: Here is the trial: https://t.co/OCg6OzBDVP
RT @JoshWalkos: Here is the trial: https://t.co/OCg6OzBDVP
Here is the trial: https://t.co/OCg6OzBDVP
Steven Kahn •Position: Advisory roles in several pharmaceutical companies •Interests: •Advisory board member for AltPep, Anji Pharmaceuticals, Boehringer Ingelheim, Eli Lilly, Intarcia, Merck, Novo Nordisk •Manuscript Title: “Semaglutide and Cardiovascular Outcomes in
Only 12 of the 15 Study Authors have direct affiliation with the drugs manufacturer Novo Nordisk. However don’t worry they have all declared that despite their conflicts of interest they in fact have none to declare. ??♂️ So ask your doctor if Novo Nordisk’s GLP-1 receptor
@lndigoVenus https://t.co/AZ90AdFkXx
In this study, the adverse heart effects started well before maximum weight loss, suggesting that it isn't *just* weight that is causing cardiovascular issues https://t.co/iX6l1EWGYF
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes | NEJM GLP-1 https://t.co/lhsVumt2lH https://t.co/w7ZmagClgU
@davethepants @agraybee sometimes the consequence is a 20% reduction in serious cardiovascular events https://t.co/AZ90AdFkXx
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes https://t.co/L5yFeh4Pek
@spektremxx A ver si leés. Lástima que tan joven requieras semaglutida y no te resultara la metformina. https://t.co/xZXyj2LisT
@msabouri Actually the largest trial on this population (SELECT trial) shows a higher SAE rate in the placebo. https://t.co/r2qzu7FEe7 https://t.co/qfOKRxvRTf
@philthatremains It actually does. Nothing you posted contradicts that. And the outcome based trials indicate that on balance not only do the benefits outweigh the side effects, its to the point where all cause mortality is higher without taking it. https://t.co/r2qzu7F6oz https://t.co/BpA4dS2aTg
@TWGarry @xJohnR_777x @Lauren_Southern https://t.co/r2qzu7F6oz https://t.co/EwJ0SJl4S8
@guima4643 @derflecha https://t.co/Wv291CcMcN
@caioveche @derflecha https://t.co/Wv291CcMcN
@Naoimportabr @derflecha https://t.co/Wv291CcMcN
@derflecha https://t.co/Wv291CcMcN
@elonmusk @cremieuxrecueil True. Amazing effects on overall health outcomes including overall death rate. https://t.co/btY67AbZKh https://t.co/ScQSg5zfJQ
RT @AF_Graphs: Evidence shows that Glp-1 drugs don’t just help you lose fat, but help with overall health, including reducing death rates:…
RT @Tetrahydropyran: @BohemianAtmosp1 Maybe you should read this instead https://t.co/fTap6fh4f4
RT @AF_Graphs: Evidence shows that Glp-1 drugs don’t just help you lose fat, but help with overall health, including reducing death rates:…
Evidence shows that Glp-1 drugs don’t just help you lose fat, but help with overall health, including reducing death rates: source: https://t.co/btY67AbZKh https://t.co/G2uPbxABAY https://t.co/j0ydkKHgvf
@BohemianAtmosp1 Maybe you should read this instead https://t.co/fTap6fh4f4
The UK @MHRAgovuk has approved use of semaglutide as used in the groundbreaking SELECT trial. Will other territories follow suit? Will there be funding for this drug indication? https://t.co/CIvLpcv8HZ https://t.co/3zxZp7JtZM
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes https://t.co/bUH3N7eLqM
However, this association was not seen in SELECT, the largest and longest CVOT for semaglutide. https://t.co/LI8L2QNGQ6
Semaglutide y resultados cardiovasculares en la obesidad sin diabetes Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes | New England Journal of Medicine https://t.co/EvYAxDTTji
✍
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes | New England Journal of Medicine https://t.co/I6Fzg6bTi1
Open Access UCL Research: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes https://t.co/n7I0kB5MNu
@realgirl_fieri I really think it might be something to discuss with your doctor! It’s not a celeb fad, it’s a heavily researched, life changing medication https://t.co/QyciAEmDHi
RT @PatrickHeizer: @mikex163 @StatisticUrban Guess you didn't read the paper, "Semaglutide and Cardiovascular Outcomes **in Obesity** witho…
RT @TubmanRf2: @StatisticUrban Important caveat: it was studied in patients with preexisting CVD who had BMI of 27 or more. Remains to be s…
RT @PatrickHeizer: @mikex163 @StatisticUrban Guess you didn't read the paper, "Semaglutide and Cardiovascular Outcomes **in Obesity** witho…
@BorisBartlog @StatisticUrban there were similar results for all-cause mortality (but you'll have to get past the paywall to see that) https://t.co/IYDA1Vl2U9
@akselerer @StatisticUrban https://t.co/IYDA1Vl2U9
@ls_fin @catpoopburglar @StatisticUrban Are you sure? The paper said they studied patients with BMI or 27 or higher. Unless I'm looking at the wrong study? https://t.co/h8VhWjYWoK
@StatisticUrban Important caveat: it was studied in patients with preexisting CVD who had BMI of 27 or more. Remains to be seen if it would have CVD protective properties in normal BMI patients. Given it's an obesity drug and obesity risk on CVD, I'm skeptical. https://t.co/h8VhWjYWoK
@mikex163 @StatisticUrban Guess you didn't read the paper, "Semaglutide and Cardiovascular Outcomes **in Obesity** without Diabetes." The semaglutide group lost 10% of their body weight, on average. https://t.co/RowvS3ufXn
2. El título del @nejm no ha podido ser más desafortunado: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes TERRIBLE https://t.co/asT1BRA0ZP
@euthymiatech @shvogt Find me a trial like this one for ozempic which shows a statistically significant reduction in mortality for any psychiatric drug, for any condition. Randomized, large sample size... https://t.co/DBqMPKf7BJ
There's a story about semaglutide that's headline news today. All well and good, but the paper it's based on was published about 6 months ago, so it's old news. I don't understand why only now is it being reported outside the specialist press?https://www.nejm.org/doi/full/10.1056/NEJMoa2307563
I assume you're talking about the same story as www.theguardian.com/science/arti..., which is about www.nejm.org/doi/full/10.... - def peer reviewed. 'mass drugging of working class people?' WTF? What actually disturbs you? (honestly, your post has strong disinfo/anti-vaxx vibes)
The paper in "NEJM", presented at the European Congress of Obesity, that the above "Guardian" article is based upon, & links to: “Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes” 2/2 https://t.co/bpfbBFfewK
RT @_anmco:
RT @_anmco:
@whatabouttheken @AliceFromQueens @MSDOSUser @dhegertz In patients who were overweight and had pre-existing CVD, it reduced heart attacks, strokes, and death by ~20% https://t.co/9nyHbCt78R
「柳叶刀：“减肥神药”司美格鲁肽或是减重最佳药物，还可治疗心衰」 司美格鲁肽（Semaglutide），是胰高血糖素样肽1（GLP-1）受体激动剂，能够模拟其作用，抑制食欲，减少饮食摄入，已经被批准用于治疗2型糖尿病与有效减重。 https://t.co/FNjdnmUAij
@hankgreen the articles that these graphs are from, for reference: https://t.co/IYDA1Vl2U9 https://t.co/7tCNxdabSR
3/ Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes | NEJM https://t.co/addQvxgMkP
RT @redGDPS: Full text links @NEJM Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes | NEJM https://t.co/lmlY1eGPkZ
RT @redGDPS: Full text links @NEJM Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes | NEJM https://t.co/lmlY1eGPkZ
RT @redGDPS: Bibliografía en @PubMedOnline https://t.co/0gGjM2qVuZ https://t.co/YVOYjDVhEC
Bibliografía en @PubMedOnline https://t.co/0gGjM2qVuZ https://t.co/YVOYjDVhEC
Full text links @NEJM Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes | NEJM https://t.co/lmlY1eGPkZ
Studienbasierte Arztbriefempfehlungen: Semaglutid-Therapie (GLP1 Analoga) zur Risikoreduktion von kardiovaskulärem Tod bei Fettleibigkeit (BMI > 27 kg/m2) ohne Diabetes SELECT-Studie: pubmed.ncbi.nlm.nih.gov/37952131/
RT @sociedadSEEN:
The landmark SELECT trial (semaglutide 2.4 mg) for patients with Obesity, CAD & no T2D. ⬇️MACE (RR ~20%); 2ndary end point "all cause mortality" significant. The immediate divergence of outcomes prior to significant weight loss is interesting . DOI: 10.1056/NEJMoa2307563 https://t.co/HagatMgnMF
RT @sociedadSEEN:
RT @sociedadSEEN:
RT @sociedadSEEN:
RT @sociedadSEEN:
RT @sociedadSEEN:
RT @deirdre_tobias: This was easily my favorite low-carb vs. low-fat trial of 2023: https://t.co/we8uVZj3RV
RT @DrRobertKushner: Enjoyed doing the Diabetes Core update podcast discussing #semaglutide and cardiovascular outcomes in #obesity without…
RT @DrRobertKushner: Enjoyed doing the Diabetes Core update podcast discussing #semaglutide and cardiovascular outcomes in #obesity without…
RT @DrRobertKushner: Enjoyed doing the Diabetes Core update podcast discussing #semaglutide and cardiovascular outcomes in #obesity without…
RT @DrRobertKushner: Enjoyed doing the Diabetes Core update podcast discussing #semaglutide and cardiovascular outcomes in #obesity without…
RT @DrRobertKushner: Enjoyed doing the Diabetes Core update podcast discussing #semaglutide and cardiovascular outcomes in #obesity without…
Enjoyed doing the Diabetes Core update podcast discussing #semaglutide and cardiovascular outcomes in #obesity without #diabetes: the #SELECT Trial. Listen here to the January podcast. @conscienhealth @NMendocrinology @AmDiabetesAssn @neilskolnik https://t.co/rxrHMnNGIR
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. https://t.co/k0bbpNMI5T #semaglutide #ozempic
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes | NEJM https://t.co/fhS8OznhWn
Fonti: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med The NANOGrav 15 yr Data Set: Evidence for a Gravitational-wave Background. Astrophys J Lett Semantic Reconstruction of Continuous Language from Non-invasive Brain Recordings. Nat Neurosci https://t.co/odbAyYtq5q
N Engl J Med 2023; 389:2221-2232 DOI: 10.1056/NEJMoa2307563 痩せ薬で有名な糖尿病薬、GLP-1受容体作動薬が、糖尿病がない患者さんの心血管イベント抑制効果を示した論文。 超肥満の方には良さそうと言う結果かな。小太りな人に効果あるか興味あります。
RT @deirdre_tobias: This was easily my favorite low-carb vs. low-fat trial of 2023: https://t.co/we8uVZj3RV
RT @deirdre_tobias: This was easily my favorite low-carb vs. low-fat trial of 2023: https://t.co/we8uVZj3RV
RT @deirdre_tobias: This was easily my favorite low-carb vs. low-fat trial of 2023: https://t.co/we8uVZj3RV
RT @deirdre_tobias: This was easily my favorite low-carb vs. low-fat trial of 2023: https://t.co/we8uVZj3RV
@MariaJonsson1 Olaglig. Åtminstone är det intressant att i en studie över cirka 3 år på icke-diabetes men överviktiga patienter med kända hjärt-kärlsjukdomar, minskade semaglutid något dödsfrekvensen eller hjärtinfarkt eller stroke (från 8,0 till 6,5%). https://t.co/9oBEIw8Bv8
RT @RevistaMFSamfyc: Semaglutida y resultados cardiovasculares en la obesidad sin diabetes https://t.co/dkcPnZVR8j PMID 37952131
This was easily my favorite low-carb vs. low-fat trial of 2023: https://t.co/we8uVZj3RV
Journal Club SID Riduzione del rischio cardiovascolare nell’obesità: i dati del trial SELECT - A cura di Danila Capoccia https://t.co/qLPtVIBLE2
RT @NEJM: Original Article: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT) https://t.co/sHpHQFO8VW Editori…
RT @muscle_penguin_: (306/347) #論文マラソン GLP-1RAは糖尿病のない肥満患者の心イベントのリスクを減らすか 45歳以上の心血管疾患患者を対象にランダム化二重盲検試験を実施。39.8か月の追跡で、セマグルチドが心血管死亡、非致死性心筋梗塞…
RT @NEJM: 2. Original Article: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes https://t.co/sHpHQFOGLu #Cardiology http…
Best of 2023 : Select Une des études qui ont marqué 2023 Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes https://t.co/zKdIOYZ309
RT @NEJM: 2. Original Article: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes https://t.co/sHpHQFOGLu #Cardiology http…
RT @NEJM: 2. Original Article: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes https://t.co/sHpHQFOGLu #Cardiology http…
RT @NEJM: 2. Original Article: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes https://t.co/sHpHQFOGLu #Cardiology http…
RT @NEJM: 2. Original Article: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes https://t.co/sHpHQFOGLu #Cardiology http…
RT @NEJM: 2. Original Article: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes https://t.co/sHpHQFOGLu #Cardiology http…
RT @NEJM: 2. Original Article: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes https://t.co/sHpHQFOGLu #Cardiology http…
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes | NEJM https://t.co/IZgQBagFOz
RT @NEJM: 2. Original Article: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes https://t.co/sHpHQFOGLu #Cardiology http…
RT @NEJM: 2. Original Article: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes https://t.co/sHpHQFOGLu #Cardiology http…
2. Original Article: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes https://t.co/sHpHQFOGLu #Cardiology https://t.co/cvW1spp7vX
RT @NEJM: Year in Review: Top 10
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
RT @NEJM: Year in Review: Top 10
RT @NEJM: Year in Review: Top 10
RT @NEJM: Year in Review: Top 10
RT @NEJM: Year in Review: Top 10
RT @NEJM: Year in Review: Top 10
RT @AMAREVA_Madrid: Comentario de @pedropabloce sobre estudio SELECT Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes –…
RT @NEJM: Year in Review: Top 10
RT @NEJM: Year in Review: Top 10 ? Posts of 2023 No. 3: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
RT @NEJM: Year in Review: Top 10
RT @NEJM: Year in Review: Top 10
RT @NEJM: Year in Review: Top 10
Year in Review: Top 10
RT @AMAREVA_Madrid: Comentario de @pedropabloce sobre estudio SELECT Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes –…
RT @AMAREVA_Madrid: Comentario de @pedropabloce sobre estudio SELECT Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes –…
Comentario de @pedropabloce sobre estudio SELECT Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes – AMAREVA – Asociación Madrileña de Riesgo y Enfermedad Vascular @Martaguillan @TGijonConde @chemachir @guso73 @mendez_bailon https://t.co/4TCnc5cfHz https://t.co/08v4MWqBVG
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes https://t.co/QOtvQoFR7t
RT @Amnesia2011: ال Ozympic و Wegovy مفيدان للقلب سواء أكنت سكرى أم لا ..... هما يستخدمان لعلاج السكر ولكن ثبت أنهما رائعين أيضآ لخفض الوزن…
ال Ozympic و Wegovy مفيدان للقلب سواء أكنت سكرى أم لا ..... هما يستخدمان لعلاج السكر ولكن ثبت أنهما رائعين أيضآ لخفض الوزن الزائد دراسة سابقة أثبتت أنهما يقللان أمراض القلب فى مرضى السكر هذه الدراسة أثبتت أنهما يقللان مخاطر أمراض القلب أيضآ فى غير السكريين https://t.co/2bTWY7juDM
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes | NEJM https://t.co/UhLYRn4YDz
RT @AAlMohammad87: Non-diabetic overweight/ obese pts with CV disease treated with #Semaglutide 2.4 mg/wk for 39.8 months: significantly re…
RT @AAlMohammad87: Non-diabetic overweight/ obese pts with CV disease treated with #Semaglutide 2.4 mg/wk for 39.8 months: significantly re…
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes | NEJM https://t.co/wHrQl0IkqL It might be usefull
Non-diabetic overweight/ obese pts with CV disease treated with #Semaglutide 2.4 mg/wk for 39.8 months: significantly reduced CVdeath/non-fatal MI/non-fatal CVA @NEJM @ShefUni_ClinMed @SheffieldHosp @Ahmed742Iqbal @BSHeartFailure #CardioTwitter https://t.co/vxtgCFB8B3
Thorp HH. More questions than answers. Science. 2023;382(6676):1213. doi:10.1126/science.adn3693 Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. doi:10.1056/NEJMoa2307563
RT @docwas: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes https://t.co/T34YiRWoqe
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes https://t.co/T34YiRWoqe
So much for obesity paradox… at least in this group of patients? N Engl J Med 2023; 389:2221-2232 DOI: 10.1056/NEJMoa2307563. Najnowsze doniesienia na zjeździe PTL przedstawione przez Prof. Małgorzata Trocha @PoLACongress @maciejbanach https://t.co/gwKVCRJtmp
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes | NEJM https://t.co/B3ICcknBTM NNT 70 to reduce sudden death MI or stroke over 3 yrs 1 in 12 AEs
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes | NEJM https://t.co/FhF7MxJCuv
RT @muscle_penguin_: (306/347) #論文マラソン GLP-1RAは糖尿病のない肥満患者の心イベントのリスクを減らすか 45歳以上の心血管疾患患者を対象にランダム化二重盲検試験を実施。39.8か月の追跡で、セマグルチドが心血管死亡、非致死性心筋梗塞…
RT @muscle_penguin_: (306/347) #論文マラソン GLP-1RAは糖尿病のない肥満患者の心イベントのリスクを減らすか 45歳以上の心血管疾患患者を対象にランダム化二重盲検試験を実施。39.8か月の追跡で、セマグルチドが心血管死亡、非致死性心筋梗塞…
(306/347) #論文マラソン GLP-1RAは糖尿病のない肥満患者の心イベントのリスクを減らすか 45歳以上の心血管疾患患者を対象にランダム化二重盲検試験を実施。39.8か月の追跡で、セマグルチドが心血管死亡、非致死性心筋梗塞、非致死性脳卒中の合併症発生率を低減した。 https://t.co/KgLHhfLJEq
RT @NEJM: Original Article: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT) https://t.co/sHpHQFO8VW Editori…
Semaglutide contra placebo en obesidad SIN diabetes. Observen las descontinuación del medicamento por eventos adverso GI December 14, 2023 N Engl J Med 2023; 389:2221-2232 DOI: 10.1056/NEJMoa2307563 https://t.co/TuNkURa8qA
RT @NEJM: Original Article: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT) https://t.co/sHpHQFO8VW Editori…
RT @NEJM: Original Article: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT) https://t.co/sHpHQFO8VW Editori…
RT @NEJM: Original Article: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT) https://t.co/sHpHQFO8VW Editori…
RT @NEJM: Original Article: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT) https://t.co/sHpHQFO8VW Editori…
RT @estebanjodar: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes | NEJM https://t.co/iNvuanWihY
RT @Nephro_Ivan: ??? Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes | NEJM https://t.co/mKb7al5NtW
RT @NEJM: Original Article: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT) https://t.co/sHpHQFO8VW Editori…
RT @NEJM: Original Article: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT) https://t.co/sHpHQFO8VW Editori…
RT @NEJM: Original Article: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT) https://t.co/sHpHQFO8VW Editori…
RT @JoseJuanatey: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes | NEJM @secardiologia https://t.co/85Mr4Qtcf4
N Engl J Med 2023; 389:2221-2232 DOI: 10.1056/NEJMoa2307563 https://t.co/CZL4vLsvvT
RT @NEJM: Original Article: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT) https://t.co/sHpHQFO8VW Editori…
??? Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes | NEJM https://t.co/mKb7al5NtW
RT @NEJM: Original Article: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT) https://t.co/sHpHQFO8VW Editori…
RT @NEJM: Original Article: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT) https://t.co/sHpHQFO8VW Editori…
RT @NEJM: Original Article: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT) https://t.co/sHpHQFO8VW Editori…
RT @NEJM: Original Article: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT) https://t.co/sHpHQFO8VW Editori…
RT @JoseJuanatey: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes | NEJM @secardiologia https://t.co/85Mr4Qtcf4
RT @NEJM: Original Article: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT) https://t.co/sHpHQFO8VW Editori…
RT @NEJM: Original Article: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT) https://t.co/sHpHQFO8VW Editori…
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. ? NEJM - 2023. doi: 10.1056/NEJMoa2307563 https://t.co/aByPwZ2hSB
RT @moreno_perez_o: ? Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes | NEJM https://t.co/xtCDW9vhUu @sociedadSEEN @sec…
RT @NEJM: Original Article: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT) https://t.co/sHpHQFO8VW Editori…
RT @NEJM: Original Article: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT) https://t.co/sHpHQFO8VW Editori…
RT @NEJM: Original Article: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT) https://t.co/sHpHQFO8VW Editori…
RT @NEJM: Original Article: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT) https://t.co/sHpHQFO8VW Editori…
RT @NEJM: Original Article: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT) https://t.co/sHpHQFO8VW Editori…
RT @NEJM: Original Article: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT) https://t.co/sHpHQFO8VW Editori…
RT @NEJM: Original Article: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT) https://t.co/sHpHQFO8VW Editori…
RT @NEJM: Original Article: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT) https://t.co/sHpHQFO8VW Editori…
RT @NEJM: Original Article: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT) https://t.co/sHpHQFO8VW Editori…
RT @moreno_perez_o: ? Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes | NEJM https://t.co/xtCDW9vhUu @sociedadSEEN @sec…
RT @NEJM: Original Article: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT) https://t.co/sHpHQFO8VW Editori…
RT @NEJM: Original Article: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT) https://t.co/sHpHQFO8VW Editori…
RT @NEJM: Original Article: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT) https://t.co/sHpHQFO8VW Editori…
RT @NEJM: Original Article: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT) https://t.co/sHpHQFO8VW Editori…
RT @NEJM: Original Article: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT) https://t.co/sHpHQFO8VW Editori…
RT @estebanjodar: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes | NEJM https://t.co/iNvuanWihY
RT @NEJM: Original Article: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT) https://t.co/sHpHQFO8VW Editori…
RT @NEJM: Original Article: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT) https://t.co/sHpHQFO8VW Editori…
RT @JoseJuanatey: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes | NEJM @secardiologia https://t.co/85Mr4Qtcf4
RT @NEJM: Original Article: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT) https://t.co/sHpHQFO8VW Editori…
RT @NEJM: Original Article: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT) https://t.co/sHpHQFO8VW Editori…
RT @NEJM: Original Article: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT) https://t.co/sHpHQFO8VW Editori…
RT @NEJM: Original Article: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT) https://t.co/sHpHQFO8VW Editori…
RT @NEJM: Original Article: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT) https://t.co/sHpHQFO8VW Editori…
RT @NEJM: Original Article: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT) https://t.co/sHpHQFO8VW Editori…
RT @NEJM: Original Article: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT) https://t.co/sHpHQFO8VW Editori…
RT @NEJM: Original Article: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT) https://t.co/sHpHQFO8VW Editori…
RT @NEJM: Original Article: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT) https://t.co/sHpHQFO8VW Editori…
RT @NEJM: Original Article: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT) https://t.co/sHpHQFO8VW Editori…
RT @NEJM: Original Article: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT) https://t.co/sHpHQFO8VW Editori…
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes | NEJM https://t.co/ep7k0Wve1a
RT @medicalport_app:
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes https://t.co/xc7y1vXIek
Semaglutida y resultados cardiovasculares en la obesidad sin diabetes https://t.co/dkcPnZVR8j PMID 37952131
RT @davidcalle1390: Pues ahora sí #arGLP1 #Semaglutida #SELECT ❤️
RT @davidcalle1390: Pues ahora sí #arGLP1 #Semaglutida #SELECT ❤️
RT @davidcalle1390: Pues ahora sí #arGLP1 #Semaglutida #SELECT ❤️
RT @davidcalle1390: Pues ahora sí #arGLP1 #Semaglutida #SELECT ❤️
Enlace directo al artículo..... https://t.co/2yWZbLE94Y
セマグルチドの皮下注によって、糖尿病のない肥満患者の心血管イベントを減らす。NNT66、NNH 11である。リベルサス皮下注2.4mg（ウゴービ）の薬価は1週間で約10740円。 #GLP1阻害薬 #NEJM Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes https://t.co/t5TJJLnHiC
GLP-1作動薬のセマグルチドを肥満の人に投与した場合には、体重減少だけでなく、心血管イベントの発生も20%低下するというNEJMの論文 皆が知りたがっていたハードアウトカムの論文が出てきました https://t.co/bN4LjCDgeB
セマグルチド（週1回のGLP1受容体作動薬）は肥満の非糖尿病患者において、心血管イベントを抑制する 本当にGLP1の薬恐るべし 副作用に消化器症状が有名ですのでご注意を。この前も直接的な因果関係は不明ですが、患者さんイレウスになってました ＃やせ薬 ＃ダイエット https://t.co/mwHcXEWZFq
Semaglutide: Promising Results in Reducing Cardiovascular Risks for Obese Patients without Diabetes https://t.co/hDmyZZDR0u
Semaglutide reduced cardiovascular events by 20% in certain adults Semaglutide reduced cardiovascular events by 20% in adults with overweight or obesity and established cardiovascular disease who do not have diabetes, according to new research. https://t.co/gbBPp8bgWB
【RCT】非糖尿病、BMI≥27、45歳以上の心血管疾患患者へのセマグルチド投与は、プラセボ投与と比較して、心血管死亡、非致死性心筋梗塞、非致死性脳卒中の複合転帰のリスクを減少させた。治療の中止につながる有害事象はセマグルチド群で多かった。 #ペ読 https://t.co/gv6v4jwO1M
RT @davidcalle1390: Pues ahora sí #arGLP1 #Semaglutida #SELECT ❤️
RT @davidcalle1390: Pues ahora sí #arGLP1 #Semaglutida #SELECT ❤️
RT @davidcalle1390: Pues ahora sí #arGLP1 #Semaglutida #SELECT ❤️
Trending on PubMed: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. https://t.co/5vYZ51iuBF
RT @nitrotake: 糖尿病の無い、肥満·過体重·心血管疾患ありに対するセマグルチドの投与は、心血管複合イベントを減らすかもしれない。 HR:0.80（95%CI,0.72-0.90）p<0.001 https://t.co/b0jn3vza2s
RT @nitrotake: 糖尿病の無い、肥満·過体重·心血管疾患ありに対するセマグルチドの投与は、心血管複合イベントを減らすかもしれない。 HR:0.80（95%CI,0.72-0.90）p<0.001 https://t.co/b0jn3vza2s
糖尿病の無い、肥満·過体重·心血管疾患ありに対するセマグルチドの投与は、心血管複合イベントを減らすかもしれない。 HR:0.80（95%CI,0.72-0.90）p<0.001 https://t.co/b0jn3vza2s
RT @davidcalle1390: Pues ahora sí #arGLP1 #Semaglutida #SELECT ❤️
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes | NEJM https://t.co/t81NVINLNv
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes https://t.co/dt5o5qR84a
RT @davidcalle1390: Pues ahora sí #arGLP1 #Semaglutida #SELECT ❤️
RT @davidcalle1390: Pues ahora sí #arGLP1 #Semaglutida #SELECT ❤️
Semaglutide reduces #cardiovascularEvents by 20% in overweight or obese adults who don't have diabetes: Trial @nejm https://t.co/kzJHpsoQ29 https://t.co/gLualZ9Vbq
https://t.co/UAydTfjioe
RT @dr_ukio: 【セマグルチド2.4mgが非DM肥満の心血管抑制(NEJM)】 SELECT試験41カ国(アジア人8%)、「CVD既往あり」非DM肥満(BMI>27, 平均33)1.7万人、34ヶ月。 ウゴービ(セマ2.4mg)vsプラセボで、 心血管複合 0.8…
RT @davidcalle1390: Pues ahora sí #arGLP1 #Semaglutida #SELECT ❤️
RT @davidcalle1390: Pues ahora sí #arGLP1 #Semaglutida #SELECT ❤️
RT @dr_ukio: 【セマグルチド2.4mgが非DM肥満の心血管抑制(NEJM)】 SELECT試験41カ国(アジア人8%)、「CVD既往あり」非DM肥満(BMI>27, 平均33)1.7万人、34ヶ月。 ウゴービ(セマ2.4mg)vsプラセボで、 心血管複合 0.8…
RT @davidcalle1390: Pues ahora sí #arGLP1 #Semaglutida #SELECT ❤️
RT @dr_ukio: 【セマグルチド2.4mgが非DM肥満の心血管抑制(NEJM)】 SELECT試験41カ国(アジア人8%)、「CVD既往あり」非DM肥満(BMI>27, 平均33)1.7万人、34ヶ月。 ウゴービ(セマ2.4mg)vsプラセボで、 心血管複合 0.8…
【セマグルチド2.4mgが非DM肥満の心血管抑制(NEJM)】 SELECT試験41カ国(アジア人8%)、「CVD既往あり」非DM肥満(BMI>27, 平均33)1.7万人、34ヶ月。 ウゴービ(セマ2.4mg)vsプラセボで、 心血管複合 0.80(0.72-0.90)。 心不全 0.82(0.71-0.96) 総死亡 0.81 (0.71-0.93) https://t.co/1z1v1fmMmR https://t.co/biHECDX1JX https://t.co/EO3Es3LSrQ
RT @davidcalle1390: Pues ahora sí #arGLP1 #Semaglutida #SELECT ❤️
RT @davidcalle1390: Pues ahora sí #arGLP1 #Semaglutida #SELECT ❤️
RT @davidcalle1390: Pues ahora sí #arGLP1 #Semaglutida #SELECT ❤️
Super interesting clinical trial results for GLP-1 agonist semaglutide’s impact on cardiovascular outcomes in patients *without* diabetes- recently published in @nejm. #epitwitter #semaglutide #medtwitter https://www.nejm.org/doi/full/10.1056/NEJMoa2307563 1/
RT @davidcalle1390: Pues ahora sí #arGLP1 #Semaglutida #SELECT ❤️
RT @davidcalle1390: Pues ahora sí #arGLP1 #Semaglutida #SELECT ❤️
RT @davidcalle1390: Pues ahora sí #arGLP1 #Semaglutida #SELECT ❤️
RT @davidcalle1390: Pues ahora sí #arGLP1 #Semaglutida #SELECT ❤️
RT @davidcalle1390: Pues ahora sí #arGLP1 #Semaglutida #SELECT ❤️
RT @davidcalle1390: Pues ahora sí #arGLP1 #Semaglutida #SELECT ❤️
RT @davidcalle1390: Pues ahora sí #arGLP1 #Semaglutida #SELECT ❤️
RT @davidcalle1390: Pues ahora sí #arGLP1 #Semaglutida #SELECT ❤️
RT @davidcalle1390: Pues ahora sí #arGLP1 #Semaglutida #SELECT ❤️
RT @davidcalle1390: Pues ahora sí #arGLP1 #Semaglutida #SELECT ❤️
RT @davidcalle1390: Pues ahora sí #arGLP1 #Semaglutida #SELECT ❤️
RT @davidcalle1390: Pues ahora sí #arGLP1 #Semaglutida #SELECT ❤️
RT @davidcalle1390: Pues ahora sí #arGLP1 #Semaglutida #SELECT ❤️
RT @davidcalle1390: Pues ahora sí #arGLP1 #Semaglutida #SELECT ❤️
RT @davidcalle1390: Pues ahora sí #arGLP1 #Semaglutida #SELECT ❤️
RT @davidcalle1390: Pues ahora sí #arGLP1 #Semaglutida #SELECT ❤️
RT @davidcalle1390: Pues ahora sí #arGLP1 #Semaglutida #SELECT ❤️
RT @davidcalle1390: Pues ahora sí #arGLP1 #Semaglutida #SELECT ❤️
RT @davidcalle1390: Pues ahora sí #arGLP1 #Semaglutida #SELECT ❤️
RT @davidcalle1390: Pues ahora sí #arGLP1 #Semaglutida #SELECT ❤️
RT @davidcalle1390: Pues ahora sí #arGLP1 #Semaglutida #SELECT ❤️
RT @davidcalle1390: Pues ahora sí #arGLP1 #Semaglutida #SELECT ❤️
RT @davidcalle1390: Pues ahora sí #arGLP1 #Semaglutida #SELECT ❤️
Can you really trust a randomized trial that can't get the law of large numbers to hold exactly?
RT @davidcalle1390: Pues ahora sí #arGLP1 #Semaglutida #SELECT ❤️
RT @davidcalle1390: Pues ahora sí #arGLP1 #Semaglutida #SELECT ❤️
RT @davidcalle1390: Pues ahora sí #arGLP1 #Semaglutida #SELECT ❤️
RT @davidcalle1390: Pues ahora sí #arGLP1 #Semaglutida #SELECT ❤️
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes ⬇️Muerte CV IAM no fatal Ictus no fatal ⬇️Mortalidad cualquier causa ⬇️IAM no fatal ⬇️Nueva revascularizacion ⬇️Endpoint renal https://t.co/S2wt27cvFR
RT @davidcalle1390: Pues ahora sí #arGLP1 #Semaglutida #SELECT ❤️
RT @davidcalle1390: Pues ahora sí #arGLP1 #Semaglutida #SELECT ❤️
RT @davidcalle1390: Pues ahora sí #arGLP1 #Semaglutida #SELECT ❤️
RT @davidcalle1390: Pues ahora sí #arGLP1 #Semaglutida #SELECT ❤️
RT @davidcalle1390: Pues ahora sí #arGLP1 #Semaglutida #SELECT ❤️
RT @davidcalle1390: Pues ahora sí #arGLP1 #Semaglutida #SELECT ❤️
RT @davidcalle1390: Pues ahora sí #arGLP1 #Semaglutida #SELECT ❤️
RT @davidcalle1390: Pues ahora sí #arGLP1 #Semaglutida #SELECT ❤️
Pues ahora sí #arGLP1 #Semaglutida #SELECT ❤️
PRINCIPAIS REFERÊNCIAS: • Lincoff et al. SELECT. NEJM 2023. DOI: 10.1056/NEJMoa2307563 • Marso et al. SUSTAIN-6. NEJM 2016. DOI: 10.1056/NEJMoa1607141 • ...
*GLP-1 trials: 10.1056/NEJMoa1607141 (type 2 diabetes) 10.1056/NEJMoa2307563 (heart health) 10.1016/S0140-6736(25)01375-3 (heart health) 10.1056 ...
doi:10.1056/NEJMoa2307563. } Comenta “GUÍA” si quieres nuestra Guía de Prescripción de Semaglutida en Obesidad, resumida y diseñada para médicos. ⚠️ ...
SCRI @ #AHA23!! SELECT results presented! https://www.nejm. org/doi/full/10.1056/NEJMoa2307563.
Semaglutide and Cardiovascular. Outcomes in Obesity without Diabetes. N Engl J Med. 2023 Dec 14;389(24):2221-2232. doi: 10.1056/NEJMoa2307563. Epub 2023 Nov. 11 ...
2023;389:2221–2232. SELECT trial. https://www.nejm.org/doi/full/10.1056/NEJMoa2307563?
... 6736(21)00213-0 [3] Lincoff et al. NEJM. 2023. DOI: 10.1056/NEJMoa2307563 [4] Wegovy Prescribing Information. 2026.".
N Engl J Med. 2023;389:2221–2232. SELECT trial. https://www.nejm.org/doi/full/10.1056/NEJMoa2307563?
doi:10.1056/NEJMoa2307563 - Carter AA, Gomes T, Camacho X, Juurlink DN, Shah BR, Mamdani MM. Risk of incident diabetes among patients ...
2023;389:2221–2232. SELECT trial. https://www.nejm.org/doi/full/10.1056/NEJMoa2307563?
... GLP-1 trials: 10.1056/NEJMoa1607141 (type 2 diabetes) 10.1056/NEJMoa2307563 (heart health) 10.1016/S0140-6736(25)01375-3 (heart health) 10.1056 ...
... 2023;389:2221–2232. DOI: 10.1056/NEJMoa2307563. #fyve #GLP1 #GLP1Journey #weightlosstips #approvedbypharmacists".
... 10.1056/NEJMoa2307563 Metabolic adaptation: https://doi.org/10.1002/oby.21538 Hunger hormones: https://doi.org/10.1056/NEJMoa1105816 Weight ...
2016.201 Semaglutide & heart: https://doi. org/10.1056/NEJMoa2307563 Metabolic adaptation: https://doi.org/10.1002/oby. 21538 Hunger ...
doi:10.1056/NEJMoa2307563. Powell-Wiley TM, et al. Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart ...
https://doi.org/10.1056/NEJMoa2307563 #CardiovascularHealth #Semaglutide #ObesityResearch #ClinicalTrial #ResearchExplained · @Article.TLDR.
Comment GLP to explore what the evidence means for your long-term health. Reference: DOI: 10.1056/NEJMoa2307563 #glp1 #longevity # ...
DOI: 10.1056/NEJMoa2307563 2. FLOW Trial — NEJM, 2024. DOI: 10.1056/NEJMoa2403347 3. ESSENCE Trial — NEJM, 2025. 4. SURMOUNT-5 Trial ...
2023;389(24):2221–2232. doi:10.1056/NEJMoa2307563. No alternative text description for this image. 2 · Like Comment. Share. Copy; LinkedIn
2016.201 Semaglutide & heart: https://doi. org/10.1056/NEJMoa2307563 Metabolic adaptation: https://doi.org/10.1002/oby. 21538 Hunger ...
Comment GLP to explore what the evidence means for your long-term health. Reference: DOI: 10.1056/NEJMoa2307563 #glp1 #longevity # ...
2023;389:2221–2232. SELECT trial. https://www.nejm.org/doi/full/10.1056/NEJMoa2307563?
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med 2023; DOI: 10.1056/NEJMoa2307563 · No photo description ...
NEJM 2023. doi:10.1056/NEJMoa2307563 SELECT: adults 45+ with cardiovascular disease, BMI ≥27, no diabetes. Don't stretch to others.
... 10.1056/NEJMoa2307563 Cite This Page: MLA APA Chicago University College London. "Weight loss drug's heart benefits extend to people with ...
SCOUT: doi.org/10.1056/NEJMoa1003114 SELECT: doi.org/10.1056/NEJMoa2307563 Dr. Bruno Mioto · CRM 112.007-SP · RQE 89316 #obesidade ...
... 10.1056/NEJMoa2307563. • Jastreboff AM et al. Posicionamento científico da Endocrine Society. Endocrine Reviews, 2026. DOI: 10.1210/endrev ...
SCOUT: doi.org/10.1056/NEJMoa1003114 SELECT: doi.org/10.1056/NEJMoa2307563 Dr. Bruno Mioto · CRM 112.007-SP · RQE 89316 #obesidade ...
New England Journal of Medicine, 2023; DOI: 10.1056/NEJMoa2307563 Cite This Page: MLA APA Chicago Cleveland Clinic. "Semaglutide reduced ...
DOI: 10.1056/NEJMoa2307563. Kahn et al. Diabetes Care. 2024. DOI: 10.2337/dc24-0491. For educational purposes only. Follow for evidence-based ...
Citations: SELECT 10.1056/NEJMoa2307563 · SELECT weight independent analysis 10.1016/S0140-6736(25)01375-3 · FLOW 10.1056/NEJMoa2403347 ...
SELECT — Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes - https://www.nejm.org/doi/full/10.1056/NEJMoa2307563 ⚠️ For ...
https://doi.org/10.1056/NEJMoa2307563 #CardiovascularHealth #Semaglutide #ObesityResearch #ClinicalTrial #ResearchExplained · @Article.TLDR · 1 ...
DOI: 10.1056/NEJMoa2307563. Kahn et al. Diabetes Care. 2024. DOI: 10.2337/dc24-0491. For educational purposes only. Follow for evidence-based ...
... 10.1056/NEJMoa2307563). But maintenance and active weight loss are two different phases, and they don't require the same dose. Once you're ...
... 10.1056/NEJMoa2307563 #CardiovascularHealth #Semaglutide #ObesityResearch #ClinicalTrial #ResearchExplained @Article.TLDR".
New Journal/article ⚫️Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes ▪️November 11, 2023 DOI: 10.1056/NEJMoa2307563 ...
org/doi/full/10.1056/NEJMoa2307563?referrer=https% 3A%2F%2Fwww.google.com%2F صحة_القلب #صحة_الكلى #حقن_التخسيس #السمنة_والسكر # ...
... 10.1056/NEJMoa2307563. Dra. Ana Elisa Crepaldi | CRM-MG 33815 | RQE 41762 | 41763 Dr. Bruno Bonaccorsi | CRM-MG 34336 | RQE 23056 | 23057 ...
... -2232. DOI: 10.1056/NEJMoa2307563. glp1 semaglutida cardiologia saudecardiovascular prevencaocardiovascular saude".
... 10.1056/NEJMoa2607978 ... Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. Journal: https://doi.org/10.1056/NEJMoa2307563
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. Journal: https://doi.org/10.1056/NEJMoa2307563 PubMed: https://pubmed.ncbi.
New Journal/article ⚫️Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes ▪️November 11, 2023 DOI: 10.1056/NEJMoa2307563 ...
2023;389:2221–2232. SELECT trial. https://www.nejm.org/doi/full/10.1056/NEJMoa2307563?
2023;389:2221–2232. SELECT trial. https://www.nejm.org/doi/full/10.1056/NEJMoa2307563?
New Journal/article ⚫️Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes ▪️November 11, 2023 DOI: 10.1056/NEJMoa2307563 ...
Most people hear GLP-1s and think about the scale. We keep coming back to muscle. A new Nature Reviews Drug Discovery paper is clear.
DOI: 10.1056/NEJMoa2307563. Like · Reply. 1 Reaction. To view or add a comment, sign in. Explore content categories. Career · Productivity ...
2023;389:2221–2232. SELECT trial. https://www.nejm.org/doi/full/10.1056/NEJMoa2307563?
DOI: 10.1056/NEJMoa2307563. Kahn et al. Diabetes Care. 2024. DOI: 10.2337/dc24-0491. For educational purposes only. Follow for evidence-based ...
DOI: 10.1056/NEJMoa2307563. Kahn et al. Diabetes Care. 2024. DOI: 10.2337/dc24-0491. For educational purposes only. Follow for evidence-based ...
A 38-year-old male, on #semaglutide, playing five-a-side weekly plus Sunday league football. No formal training programme before this.
doi:10.1056/NEJMoa2307563. } Comenta “GUÍA” si quieres nuestra ... Te leo en comentarios. Ref: Lincoff AM, et al. N Engl J Med. 2023; 389: ...
... 10.1056/NEJMoa2307563. Metra M, et al. SGLT2 Inhibitors for the Prevention and Treatment of Heart Failure. ESC Heart Failure. 2025. Why this ...
SELECT — Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes - https://www.nejm.org/doi/full/10.1056/NEJMoa2307563 ⚠️ For ...
2023;389:2221–2232. SELECT trial. https://www.nejm.org/doi/full/10.1056/NEJMoa2307563?
doi:10.1056/NEJMoa2307563. Why this matters: This large RCT showed fewer major cardiovascular events, not proven slowing of biological aging ...
Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med. 2023;389(24):2221–2232. doi:10.1056/NEJMoa2307563.
SELECT — Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes - https://www.nejm.org/doi/full/10.1056/NEJMoa2307563 ⚠️ For ...
DOI: 10.1056/NEJMoa2307563. Kahn et al. Diabetes Care. 2024. DOI: 10.2337/dc24-0491. For educational purposes only. Follow for evidence-based ...
... 10.1056/NEJMoa2307563). But maintenance and active weight loss are two different phases, and they don't require the same dose. Once you're ...
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389:2221-2232. doi:10.1056/NEJMoa2307563. 3. DO-HEALTH: ...
2023;389:2221–2232. SELECT trial. https://www.nejm.org/doi/full/10.1056/NEJMoa2307563?
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. Journal: https://doi.org/10.1056/NEJMoa2307563 PubMed: https://pubmed ...
everyone I love all the research that's coming out |https://www.nejm.org/doi/full/10.1056/NEJMoa2307563 ...
Journal: https://doi.org/10.1056/NEJMoa2307563 PubMed: https://pubmed.ncbi.nlm.nih.gov/37952131/. September 16. Accounts you might like.
E10: SELECT, doi:10.1056/NEJMoa2307563; ESSENCE, doi:10.1056/NEJMoa2413258; BELIEVE as above. Sources also appear on the relevant slides ...
... 10.1056/NEJMoa2413258 2. Loomba R et al. N Engl J Med. 2024 ... doi:10.1056NEJMoa2307563 5. Nicholls SJ et al. N Engl J Med.2025;393 ...
And GLP-1s carry real metabolic upside beyond the scale, including lower cardiovascular events (DOI 10.1056/NEJMoa2307563). But the combo ...
DOI:10.1056/NEJMoa2307663 https://doi.org/10.1056/NEJMoa2307563. Você já sabia sobre esses benefícios? Conte-me nos comentários!. View ...
Citations: SELECT 10.1056/NEJMoa2307563 · SELECT weight independent analysis 10.1016/S0140-6736(25)01375-3 · FLOW 10.1056/NEJMoa2403347 ...
https://doi.org/10.1056/NEJMoa2307563 #CardiovascularHealth #Semaglutide #ObesityResearch #ClinicalTrial #ResearchExplained · @Article.TLDR.
E09: FDA Foundayo and Wegovy prescribing information, 2026. E10: SELECT, doi:10.1056/NEJMoa2307563; ESSENCE, doi:10.1056/NEJMoa2413258; BELIEVE ...
... 10.1056/NEJMoa2307563 #agelessmenshealth #glp1 #metabolichealth #preventativehealth #semaglutide GLP-? medications are ...
SELECT — Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes - https://www.nejm.org/doi/full/10.1056/NEJMoa2307563 ⚠️ For ...
https://doi.org/10.1056/NEJMoa2307563 #CardiovascularHealth #Semaglutide #ObesityResearch #ClinicalTrial #ResearchExplained · @Article.TLDR.
doi:10.1056/NEJMoa2307563 #SaudiHealthcare #Vision2030 #HealthcareTransformation #CardiacSurgery #CardiovascularCare #HospitalLeadership ...
Citations: SELECT 10.1056/NEJMoa2307563 · SELECT weight independent analysis 10.1016/S0140-6736(25)01375-3 · FLOW 10.1056/NEJMoa2403347 ...
... 10.1056/NEJMoa2307563. Newsletter. Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical ...
2023;389(24):2221–2232. doi:10.1056/NEJMoa2307563. No alternative text description for this image. 2 · Like Comment. Share. Copy; LinkedIn
doi:10.1056/NEJMoa2307563. } Comenta “GUÍA” si quieres nuestra Guía de Prescripción de Semaglutida en Obesidad, resumida y diseñada para ...
E09: FDA Foundayo and Wegovy prescribing information, 2026. E10: SELECT, doi:10.1056/NEJMoa2307563; ESSENCE, doi:10.1056/NEJMoa2413258; BELIEVE ...
2023;389(24):2221–2232. doi:10.1056/NEJMoa2307563. No alternative text description for this image. 2 · Like Comment. Share. Copy; LinkedIn
org/doi/full/10.1056/NEJMoa2307563 (published Nov 2023) A promising drug for the treatment of obesity but we must not forget the importance ...
doi:10.1056/NEJMoa2307563. } Comenta “GUÍA” si quieres nuestra ... Te leo en comentarios. Ref: Lincoff AM, et al. N Engl J Med. 2023; 389: ...
And GLP-1s carry real metabolic upside beyond the scale, including lower cardiovascular events (DOI 10.1056/NEJMoa2307563). But the combo ...
New Journal/article ⚫️Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes ▪️November 11, 2023 DOI: 10.1056/NEJMoa2307563 ...
SELECT — Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes - https://www.nejm.org/doi/full/10.1056/NEJMoa2307563 ⚠️ For ...
New Journal/article ⚫️Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes ▪️November 11, 2023 DOI: 10.1056/NEJMoa2307563 ...
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM. https://doi.org/10.1056/NEJMoa2307563. Wilding JPH et al. (2022).
SELECT — Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes - https://www.nejm.org/doi/full/10.1056/NEJMoa2307563 ⚠️ For ...
New England Journal of Medicine, 2023; DOI: 10.1056/NEJMoa2307563 Cite This Page: MLA APA Chicago Cleveland Clinic. "Semaglutide reduced ...
New England Journal of Medicine, 2023; 389 (24): 2221 DOI: 10.1056/NEJMoa2307563; John Deanfield, A Michael Lincoff, Steven E Kahn, Scott S ...
https://www.nejm.org/doi/full/10.1056/NEJMoa2307563. Journal. The Lancet. Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy ...
doi:10.1056/NEJMoa2307563. } Comenta “GUÍA” si quieres nuestra Guía de Prescripción de Semaglutida en Obesidad, resumida y diseñada para ...
DOI: 10.1056/NEJMoa2307563. Sanyal AJ et al. ESSENCE. _N Engl J Med._ 2025. DOI: 10.1056/NEJMoa2413258. Loomba R et al. SYNERGY-NASH. _N ...
doi:10.1056/NEJMoa2307563. Supporting quotes: “GLP-1s are transforming the treatment of obesity, with immense potential for weight loss and ...
doi:10.1056/NEJMoa2307563. ###. About the American Society for Nutrition (ASN). ASN is the preeminent professional organization for nutrition ...
org/doi/full/10.1056/NEJMoa2307563. nejm.org. Semaglutide and Cardiovascular Outcomes in. 1y. SoulHealth. Even the FDA has approved it as a ...
... hela studien här: https://www.nejm. org/doi/full/10.1056/NEJMoa2307563. nejm.org. Semaglutide and Cardiovascular Outcomes in. 1y. 4. Olga ...
... 10.1056/NEJMoa2307563 Cite This Page: MLA APA Chicago University College London. "Weight loss drug's heart benefits extend to people with ...
doi:10.1056/NEJMoa2307563. } Comenta “GUÍA” si quieres nuestra Guía de Prescripción de Semaglutida en Obesidad, resumida y diseñada para ...
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. doi: 10.1056/NEJMoa2307563. Ryan DH, ...
New England Journal of Medicine, 2023; DOI: 10.1056/NEJMoa2307563 Cite This Page: MLA APA Chicago Cleveland Clinic. "Semaglutide reduced ...
... 10.1056/NEJMoa2032183 [2] https://www.nejm.org/doi/full/10.1056/NEJMoa2307563 [3] Các nghiên cứu của khôi nguyên giải thưởng Lasker-DeBakey ...
New England Journal of Medicine, 2023; DOI: 10.1056/NEJMoa2307563 Cite This Page: MLA APA Chicago Cleveland Clinic. "Semaglutide reduced ...
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023 Dec 14;389(24):2221-2232. doi: 10.1056/NEJMoa2307563.
org/doi/full/10.1056/NEJMoa2307563#ap0 Si te ha gustado el contenido, compártelo con quien pienses pueda interesarle. Hasta luego ...
New England Journal of Medicine, 2023; 389 (24): 2221 DOI: 10.1056/NEJMoa2307563. Cite This Page: MLA; APA; Chicago. University College London ...
URL : https://www.nejm.org/doi/10.1056/NEJMoa2307563 DOI: 10.1056/NEJMoa2307563 Thank you in advance.
DOI: 10.1056/NEJMoa2307563. Like · Reply · 1 Reaction 2 Reactions. To view or add a comment, sign in. Explore content categories. Career ...
DOI- 10.1056/NEJMoa2307563 URL- https://www.nejm.org/doi/full/10.1056/NEJMoa2307563.
New Journal/article ⚫️Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes ▪️November 11, 2023 DOI: 10.1056/NEJMoa2307563 ...
New Journal/article ⚫️Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes ▪️November 11, 2023 DOI: 10.1056/NEJMoa2307563 ...
... 10.1056/NEJMp2300516">Medicare Part D Coverage of ... NEJMoa2307563">Semaglutide and Cardiovascular Outcomes in ...
The New England Journal of Medicine. Published online November 11, 2023. doi: 10.1056/NEJMoa2307563. M. Sodhi et al. Risk of gastrointestinal ...
... 10.1056/NEJMoa2307563?query=featured_home #AHA2023. Log in ... org/doi/full/10.1056/NEJMoa2307563?query=feature d_home #AHA2023. อาจ ...
The New England Journal of Medicine. Published online November 11, 2023. doi: 10.1056/NEJMoa2307563. Meghan Rosen headhsot. About Meghan Rosen.
DOI: 10.1056/NEJMoa2307563. Amit Khera et al, SELECTing Treatments for Cardiovascular Disease—Obesity in the Spotlight, New England Journal ...
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine, 2023; DOI: 10.1056/NEJMoa2307563. Cite ...
DOI: 10.1056/NEJMoa2307563. Journal information: New England Journal of Medicine. Key medical concepts. SemaglutideCardiovascular Diseases.
New Journal/article ⚫️Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes ▪️November 11, 2023 DOI: 10.1056/NEJMoa2307563 ...
glp Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes 23 https://www.nejm.org/doi/full/10.1056/NEJMoa2307563 SELECT（RCT, ...
2023;doi:10.1056/NEJMoa2307563. Khera A, Powell-Wiley TM. N Engl J Med. 2023;doi:10.1056/NEJMe2312646. Perspective. Back to Top. Erin D ...
... diabetes" N Eng J Med 2023; DOI: 10.1056/NEJMoa2307563. 14. 14 Comments. Please enable JavaScript to view the comments powered by Disqus.
org/doi/pdf/10.1056/NEJMoa2307563?articl eTools=true ... New England Journal of Medicine, 2023; DOI: 10.1056/NEJMoa2307563 Cite This Page: MLA APA ...
New England Journal of Medicine, 2023; DOI: 10.1056/NEJMoa2307563 Cite This Page: MLA APA Chicago Cleveland Clinic. "Semaglutide reduced ...
New England Journal of Medicine, 2023; DOI: 10.1056/NEJMoa2307563 Cite This Page: MLA APA Chicago Cleveland Clinic. "Semaglutide reduced ...
org/doi/full/10.1056/NEJMoa2307563 (published Nov 2023) A promising drug for the treatment of obesity but we must not forget the importance ...
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med 2023; DOI: 10.1056/NEJMoa2307563 · No photo description ...
DW
JW
MC
M
MR
EB
DW
D
PD
AM
ML
I
PP
MN
FB
LJ
ち
JD
TL
AD
JN
C
秀
MB
WR
CP
AT
AI
P
DD
DA
LR
T
研T
AI
DS
KM
BS
GO
DF
BR
BS
KB
PU
DM
D
M
M
GH
FM
WF
MM
つ
T
FP
TO
LM
MS
JR
C
SF
S
DC
JM
AP
DG
IV
SM
HF
R
CM
JS
AA
JM
E
JY
JC
C
MM
J
MY
AM
M
Fا
AC
CM
JS
CU
KS
EA
カ七
MV
QA
WL
MF
GF
RL
WB
M
แว
KS
BL
FS
DM
ノม
NM